Time to antiretroviral therapy initiation in HIV-positive patients with opportunistic infections/AIDS-defining illness in Southern Thailand: a prospective cohort study

被引:0
|
作者
Wuttikul, Chanadda [1 ,2 ]
Thanawuth, Nattasiri [1 ]
Rojpibulsatit, Malee [1 ]
Pattharachayakul, Sutthiporn [1 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Clin Pharm, Hat Yai, Songkhla, Thailand
[2] Univ Phayao, Sch Pharmaceut Sci, Dept Pharmaceut Care, Div Clin Pharm, Phayao, Thailand
来源
HIV & AIDS REVIEW | 2024年 / 23卷 / 03期
关键词
antiretroviral therapy; opportunistic infections; AIDS-defining illnesses; co-infection; time to antiretroviral therapy initiation; SEXUAL-BEHAVIORS; IMPACT; CARE; RETENTION; BELIEFS; LINKAGE;
D O I
10.5114/hivar.2024.138827
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Rapid antiretroviral therapy (ART) initiation is recommended for all people living with human immunodeficiency virus (HIV). Time to ART initiation in individual patients depends on several factors. The study objectives were to investigate the time to ART initiation in HIV-positive patients with opportunistic infections/AIDS-defining illnesses (OIs/ADI), and associated factors. Material and methods: A prospective cohort study was performed among ART-na & iuml;ve HIV patients with OIs/ADI. Time to ART initiation was defined as the time from being diagnosed with OIs/ADI to Results: A total of 253 patients were included. The three most common OIs were tuberculosis (36.8%), Pneumocystis jirovecii pneumonia (26.1%), and candidiasis (19.0%). 39.9% of patients learned about their HIV-serostatus after OIs/ADI diagnosis. The median time from OIs/ADI diagnosis to ART initiation was 38 days (IQR, 23-71). From Cox regression model, the factor independently associated with a shorter waiting time to ART initiation was continuous engagement in HIV care (aHR = 2.42; 95% CI: 1.70-3.45%). On the other hand, the factors associated with a longer time to ART initiation were tuberculosis co-infection (aHR = 0.52; 95% CI: 0.36-0.75%), HIV diagnosis after OIs/ADI (aHR = 0.42; 95% CI: 0.30-0.57%), viral hepatitis B/C co-infection (aHR = 0.59; 95% CI: 0.39-0.89%), seeking care in general hospital and community hospital (aHR = 0.67; 95% CI: 0.49-0.93%, and aHR = 0.62; 95% CI: 0.44-0.86%, respectively), having more than one hospital admission in the past six months (aHR = 0.60; 95% CI: 0.44-0.81%), and history of missed appointments (aHR = 0.62; 95% CI: 0.42-0.91%). Conclusions: To achieve maximal benefits of ART, strategies to improve HIV awareness, continuous care engagement, and timely ART initiation are required.
引用
收藏
页码:226 / 232
页数:7
相关论文
共 50 条
  • [21] Test site predicts HIV care linkage and antiretroviral therapy initiation: a prospective 3.5 year cohort study of HIV-positive testers in northern Tanzania
    Reddy, Elizabeth A.
    Agala, Chris Bernard
    Maro, Venance P.
    Ostermann, Jan
    Pence, Brian W.
    Itemba, Dafrosa K.
    Safley, Donna
    Yao, Jia
    Thielman, Nathan M.
    Whetten, Kathryn
    BMC INFECTIOUS DISEASES, 2016, 16
  • [22] Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults
    Crum-Cianflone, Nancy F.
    Wang, Xun
    Ganesan, Anuradha
    Okulicz, Jason
    Weintrob, Amy
    Lalani, Tahaniyat
    Agan, Brian
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2015, 31 (05) : 514 - 518
  • [23] EARLY OR DEFERRED ZIDOVUDINE THERAPY IN HIV-INFECTED PATIENTS WITHOUT AN AIDS-DEFINING ILLNESS - A METAANALYSIS
    IOANNIDIS, JPA
    CAPPELLERI, JC
    LAU, J
    SKOLNIK, PR
    MELVILLE, B
    CHALMERS, TC
    SACKS, HS
    ANNALS OF INTERNAL MEDICINE, 1995, 122 (11) : 856 - 866
  • [24] Adherence to Antiretroviral Therapy in HIV-Positive Adolescents in Uganda Assessed by Multiple Methods A Prospective Cohort Study
    Wiens, Matthew O.
    MacLeod, Stuart
    Musiime, Victor
    Ssenyonga, Mark
    Kizza, Ruth
    Bakeera-Kitaka, Sabrina
    Odoi-Adome, Richard
    Ssali, Francis
    PEDIATRIC DRUGS, 2012, 14 (05) : 331 - 335
  • [25] Adherence to Antiretroviral Therapy in HIV-Positive Adolescents in Uganda Assessed by Multiple MethodsA Prospective Cohort Study
    Matthew O. Wiens
    Stuart MacLeod
    Victor Musiime
    Mark Ssenyonga
    Ruth Kizza
    Sabrina Bakeera-Kitaka
    Richard Odoi-Adome
    Francis Ssali
    Pediatric Drugs, 2012, 14 (5) : 331 - 335
  • [26] Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy
    Galli, Laura
    Spagnuolo, Vincenzo
    Poli, Andrea
    Salpietro, Stefania
    Gianotti, Nicola
    Cossarini, Francesca
    Carbone, Alessia
    Nozza, Silvia
    Bossolasco, Simona
    Bigoloni, Alba
    Lazzarin, Adriano
    Castagna, Antonella
    AIDS, 2014, 28 (16) : 2407 - 2415
  • [27] When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries An Observational Study
    Cain, Lauren E.
    Logan, Roger
    Robins, James M.
    Sterne, Jonathan A. C.
    Sabin, Caroline
    Bansi, Loveleen
    Justice, Amy
    Goulet, Joseph
    van Sighem, Ard
    de Wolf, Frank
    Bucher, Heiner C.
    von Wyl, Viktor
    Esteve, Anna
    Casabona, Jordi
    del Amo, Julia
    Moreno, Santiago
    Seng, Remonie
    Meyer, Laurence
    Perez-Hoyos, Santiago
    Muga, Roberto
    Lodi, Sara
    Lanoy, Emilie
    Costagliola, Dominique
    Hernan, Miguel A.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) : 509 - 515
  • [28] Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIV-positive mothers: a cohort study
    Myer, Landon
    Zulliger, Rose
    Bekker, Linda-Gail
    Abrams, Elaine
    BMC PREGNANCY AND CHILDBIRTH, 2012, 12
  • [29] Why are HIV-positive patients hospitalized with severe infections not on highly active antiretroviral therapy?
    Chaggar, T.
    Haddow, L.
    Chandna, A.
    Chaggar, P.
    Al-Chalabi, H.
    McGregor, A.
    Edwards, S.
    Cartledge, J.
    HIV MEDICINE, 2010, 11 : 61 - 61
  • [30] Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIV-positive mothers: a cohort study
    Landon Myer
    Rose Zulliger
    Linda-Gail Bekker
    Elaine Abrams
    BMC Pregnancy and Childbirth, 12